Abstract:Histone deacetylase inhibitors (HDACi) such as trichostatin A (TSA) and Sodium Butyrate (NaB) can regulate gene expression by acetylating histones and transcription factors. HDACi attenuate expression of certain NF-kB-regulated cytokines, including TNF-α, IL-1β, IL-6, and IFN-γ in some inflammatory disease models. Human tissue fatctor (TF) expression is, in part, governed by a unique, NF-kB-related “TF-kB” promoter binding site. We hypothesized that HDACi would inhibit induction of TF expression by physiologic agonists. We assessed the effect of TSA and NaB upon TF expression in human umbilical vein endothelial cells (HUVEC) and peripheral blood mononuclear cells (PBM) in response to 1 ng/ml TNF-α, 1 ng/ml IL-1β, 1 μg/ml LPS, and 100 μM HOSCN, a potent phagocyte peroxidase-derived oxidant. HUVEC monlayers and PBM were pretreated with TSA (0.01–1 μM) or NaB (1–10 mM) for 4 h prior to agonist addition and 4 h later whole cell lysates were assayed for TF activity by 1-stage clotting assay and western blots probed for TF. Both TSA and NaB inhibit HUVEC TF activity and protein expression up to 90% with respective IC50's of 30–50 nM and 2 mM. TSA decreases PBM TF activity induced by LPS and IL-1β by 50–65% with similar potency. In striking contrast, western blots show no effect of TSA on agonist-induced expression of the NF-kB-regulated adhesion molecules ICAM-1 and E-selectin. RT-PCR analysis shows TNF-α stimulation induces a 22-fold increase of TF mRNA that is attenuated up to 70% by TSA treatment without affecting the 10-fold ICAM-1 mRNA increase. TSA did not influence TF translational efficiency as detected by polyribosomal TF mRNA distribution and TSA TF inhibition was unaffected by the ubiquitin-dependent protein degradation inhibitor MG-132. EMSA analysis of HUVEC nuclear extracts using probes for the SP1, AP-1, Egr-1 and TF-kB transcription factor binding sites in the TF gene promoter shows that SP1, AP-1 and Egr-1 are constitutively activated in HUVEC and are unaffected by LPS or TNF-α irrespective of whether TSA is present. However, both TNF-α and LPS induce abundant p65/p50 and p65/c-Rel heterodimer binding to both the NF-kB and TF-kB probes. 0.3 μM TSA nearly completely abolishes TF-kB activation without affecting NF-kB activation. TSA has no effect on TNF-α-induced cytoplasmic IkB-α degradation or nuclear translocation of c-Rel, p65, or p50. Chromatin immunoprecipitation assay shows that TSA strongly inhibits p65 binding to the authentic endogenous HUVEC TF-kB site in the TF promoter induced by TNF-α without affecting p65 binding to the ICAM-1 NF-kB site. A HUVEC promoter-luciferase reporter system confirms the complete specificity of TSA's inhibitory effect on LPS- or TNF-α- induced TF expression for TF-kB rather than NF-kB. We conclude that HDACi transcriptionally inhibit agonist-induced TF expression in human endothelial cells and monocytes by specific blockade of TF-kB activation. We propose that histone deacetylases play a previously unsuspected role in regulating TF expression and HDACi might be a novel therapy for thrombotic diseases.

Dual Effects Of Histone Deacetylase Inhibition By Trichostatin A On Endothelial Nitric Oxide Synthase Expression In Endothelial Cells

Effects of trichostatin A on the expressions of inflammatory cytokines and toll-like receptor 4 and the acetylation of nuclear factor-κB induced by lipopolysaccharide in macrophage

Inhibition of Histone Deacetylases Prevents Cardiac Remodeling After Myocardial Infarction by Restoring Autophagosome Processing in Cardiac Fibroblasts.

Role of histone deacetylation in cell-specific expression of endothelial nitric-oxide synthase.

Effects of Trichostatin A on Expression of Proinflammatory Cytokines in Hearts and Cardiac Function in Rats with Heart Failure

Effects of Trichostatin A on the Interaction Between HBx and Histone Deacetylase Protein 1

[The Effects of a Histone Deacetylase (HDAC) Inhibitor on Endotoxin-Induced Endothelial Cell Injury].

Transcriptional modulation of monoaminergic neurotransmission genes by the histone deacetylase inhibitor trichostatin A in neuroblastoma cells

Effects of Histone Deacetylase Inhibitor Trichostatin A on Proliferation and Adipogenic Differentiation of C3H10T1/2 Mesenchymal Stem Cells

“Tf-Kb”-dependent Suppression of Agonist-Mediated Tissue Factor Induction by Histone Deacetylase Inhibitors in Human Endothelial Cells and Monocytes.

Trichostatin A Destabilizes HIF-2α Through a VHL-independent but Proteasome-Dependent Pathway in Cancer Cell Lines and Tumor Xenografts

Trichostatin A Improves Insulin Stimulated Glucose Utilization and Insulin Signaling Transduction Through the Repression of HDAC2.

The Histone Deacetylase Inhibitor Tubacin Mitigates Endothelial Dysfunction by Up-Regulating the Expression of Endothelial Nitric Oxide Synthase

Synergistic Induction of Apoptosis by HMG-CoA Reductase Inhibitor and Histone Deacetylases Inhibitor in HeLa Cells.

Effect of Trichostatin A on p27kip1 Expression in Vascular Smooth Muscle Cells

Trichostatin A, a Histone Deacetylase Inhibitor, Attenuates Invasiveness and Reactivates E-Cadherin Expression in Immortalized Endometriotic Cells

Histone Deacetylase Inhibitors Suppress TF-κB-dependent Agonist-driven Tissue Factor Expression in Endothelial Cells and Monocytes

Trichostatin A, a Histone Deacetylase Inhibitor, Alleviates Eosinophilic Meningitis Induced by Angiostrongylus Cantonensis Infection in Mice

[Effect of Trichostatin A on Histone Acetylation Level and Apoptosis in HL-60 Cells].

Promoter specific sensitivity to inhibition of histone deacetylases: implications for hormonal gene control, cellular differentiation and cancer

Abstract 325: The Regulation of Endothelial Function Through Hmgcr/mevalonate Pathway Mediated Yap Activity